Orchid Pharma share price has zoomed 6% and is presently trading at Rs 1,600.0.
Meanwhile, the BSE HEALTHCARE index is at 43,216.3 (down 0.4%).
Among the top gainers in the BSE HEALTHCARE index today are MAX HEALTHCARE INSTITUTE (up 2.9%) and CAPLIN POINT (up 2.5%).
POLY MEDICURE (down 7.4%) and IPCA Labs (down 2.2%) are among the top losers today.
Over the last one year, Orchid Pharma has moved up from Rs 588.8 to Rs 1,600.0, registering a gain of Rs 1,011.3 (up 171.8%).
On the other hand, the BSE HEALTHCARE index has moved up from 29,918.9 to 43,216.3, registering a gain of 44.4% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 164.5%), SUVEN PHARMACEUTICALS (up 110.6%) and Glenmark Pharma (up 93.3%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 80,012.8 (down 0.1%).
The top losers among the BSE Sensex today are Ultratech Cement (down 2.3%) and MUNDRA PORT & SEZ (down 2.1%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,201.3 (down 0.1%). Ultratech Cement and Adani Enterprises are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,023.2 to 80,012.8, registering a gain of 13,989.5 points (up 21.2%).
Orchid Pharma net profit grew 29.3% YoY to Rs 259 million for the quarter ended September 2024, compared to a profit of Rs 200 million a year ago. Net sales rose 12.0% to Rs 2,227 million during the period as against Rs 1,988 million in July-September 2023.
For the year ended March 2024, Orchid Pharma reported 72.1% increase in net profit to Rs 951 million compared to net profit of Rs 552 million during FY23. Revenue of the company grew 23.0% to Rs 8,194 million during FY24.
The current Price to earnings ratio of Orchid Pharma, based on rolling 12 month earnings, stands at 68.8.
Equitymaster requests your view! Post a comment on "Orchid Pharma Gains 6%; BSE HEALTHCARE Index Down 0.4%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!